{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:25:46Z","timestamp":1793305546182,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ygyno.2019.09.015","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T18:03:11Z","timestamp":1571767391000},"page":"393-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384)\u00a0+ OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology\/GOG study"],"prefix":"10.1016","volume":"155","author":[{"given":"Roisin E.","family":"O\u2019Cearbhaill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-may","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Joseph A.","family":"Lucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian","family":"Behbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick M.","family":"Spirtos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Y.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict B.","family":"Benigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnansu S.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parviz","family":"Hanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Lankes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.09.015_bib1","series-title":"Principles and Practice of Gynecologic Oncology","author":"Hoskins","year":"2000"},{"key":"10.1016\/j.ygyno.2019.09.015_bib2","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.09.015_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"14","key":"10.1016\/j.ygyno.2019.09.015_bib4","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1158\/1078-0432.CCR-06-2949","article-title":"Pilot study of a heptavalent vaccine-KLH conjugate plus QS-21 in patients with epithelial ovarain, fallopian tube, or peritoneal cancer","volume":"13","author":"Sabbatini","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.09.015_bib5","series-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0","author":"Institute","year":"2009"},{"key":"10.1016\/j.ygyno.2019.09.015_bib6","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.EPI-09-0880","article-title":"p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer","volume":"19","author":"Anderson","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2019.09.015_bib7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2005.04.5138","article-title":"Consolidation for ovarian cancer in remission","volume":"24","author":"Sabbatini","year":"2006","journal-title":"J.\u00a0Clin. Oncol. : Off. J. American. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.09.015_bib8","first-page":"271","article-title":"Ovarian cancer: current treatment and patient management","volume":"7","author":"Monk","year":"2016","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"10.1016\/j.ygyno.2019.09.015_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/IGC.0b013e31822e29aa","article-title":"Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission","volume":"22","author":"Iasonos","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.09.015_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.09.015_bib11","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.09.015_bib12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A\u00a0multiple testing procedure for clinical trials","volume":"35","author":"O\u2019Brien","year":"1979","journal-title":"Biometrics"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819315367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819315367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:46:54Z","timestamp":1758772014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819315367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0090825819315367"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.09.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384)\u00a0+ OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology\/GOG study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}